Your search history is turned on.
Date: May 1, 2024 Jurisdictions: Alberta, British Columbia, Manitoba, Ontario
Pancreatic Cancer: Successful Trial Against Pancreatic Cancer with Defence Therapeutics' ARM-002 Anti-Cancer Vaccine Vancouver, British Columbia--(Newsfile Corp. - May 1, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology therapeutics and drug delivery technologies, is pleased t...
Date: April 23, 2024 Jurisdictions: Alberta, British Columbia, Manitoba, Ontario
Defence's AccuTOX Anti-Cancer ARM-002 Vaccine Exhibits Potent Antigen Presentation Vancouver, British Columbia--(Newsfile Corp. - April 23, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology therapeutics and drug delivery technologies, is pleased to announce that its second-gener...
Date: April 17, 2024 Jurisdictions: Alberta, British Columbia, Manitoba, Ontario
Defence Therapeutics Signs with German Based FMS Consult GmbH for Financing Strategy to Support Defence Pipeline Growth Vancouver, British Columbia--(Newsfile Corp. - April 17, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology therapeutics and drug delivery technologies, is plea...
Date: April 10, 2024 Jurisdictions: British Columbia, Quebec
Amend Report of Exempt Distribution Form 45-106F1 Form 45-106F1 Report of Exempt Distribution ITEM 1 REPORT TYPE New report Amended report If amended, provide filing date of report that is being amended. 2024 04 01 (YYYY-MM-DD) ITEM 2 PARTY CERTIFYING THE REPORT Indicate the party certifying the report (select only one). For guidance regarding whet...
Date: April 5, 2024 Jurisdictions: Alberta, British Columbia, Manitoba, Ontario
Defence Therapeutics Announces Warrant Terms Amendment Vancouver, British Columbia--(Newsfile Corp. - April 5, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), one of the leading Canadian biotechnology companies working in the field of immune-oncology, announces an amendment to the terms of 1,497,780 Class A Common share purchase warrants (the "W...
Date: April 1, 2024 Jurisdictions: Alberta, British Columbia, Manitoba, Ontario
SECURITIES ACT FORM 51-102F3 MATERIAL CHANGE REPORT Item 1 Name and Address of Company Defence Therapeutics Inc. (the Issuer) 200 Burrard Street, Suite 680 Vancouver, BC V6C 3L6 Item 2 Date of Material Change March 22nd, 2024 Item 3 News Release A news release was disseminated via a Canadian ne...
Date: April 1, 2024 Jurisdictions: British Columbia, Quebec
Create report of exempt distribution (Form 45-106F1) Form 45-106F1 Report of Exempt Distribution ITEM 1 - REPORT TYPE New report Amended report If amended, provide filing date of report that is being amended. (YYYY-MM-DD) ITEM 2 - PARTY CERTIFYING THE REPORT Indicate the party certifying the report (select only one). For guidance regarding whether an ...
Date: March 26, 2024 Jurisdictions: Alberta, British Columbia, Manitoba, Ontario
Defence's Successful Results on Its AccuTOX Anti-Cancer ARM Vaccine Creates a Potent Second-Generation Anti-Cancer ARM-002 Vaccine Vancouver, British Columbia--(Newsfile Corp. - March 26, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biotechnology company developing novel immune-oncology therapeutics and drug delivery technologies, ...
Date: March 22, 2024 Jurisdictions: Alberta, British Columbia, Manitoba, Ontario
Defence Completes 2nd Tranche of Financing Vancouver, British Columbia--(Newsfile Corp. - March 22, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), one of the leading Canadian biotechnology companies working in the field of immune-oncology, announces the closing of the 2nd tranche of its previously announced non-brokered private placement (the ...
Date: February 29, 2024 Jurisdictions: Alberta, British Columbia, Manitoba, Ontario
Defence Announces Peer-Reviewed Publication on Accum-E7 Anti-Cancer Vaccine in Cancer Science Journal and Financing Update Vancouver, British Columbia--(Newsfile Corp. - February 29, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), one of the leading Canadian biotechnology companies working in the field of immune-oncology, is pleased to announce ...